Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma

As CD20 has become an established target for treating B‐cell malignancies, there is interest in developing anti‐CD20 antibodies with different functional activity from rituximab that might translate into improved efficacy. Obinutuzumab (GA101) is a glycoengineered, humanized type II anti‐CD20 monocl...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Sci
Main Authors: Ogura, Michinori, Tobinai, Kensei, Hatake, Kiyohiko, Uchida, Toshiki, Suzuki, Tatsuya, Kobayashi, Yukio, Mori, Masakazu, Terui, Yasuhito, Yokoyama, Masahiro, Hotta, Tomomitsu
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2012
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657177/
https://ncbi.nlm.nih.gov/pubmed/23046388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12040
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki